This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Professor John Wallace PhD MBA

Professor John Wallace PhD MBA


Professor John Wallace PhD MBA HonFBPhS


University of Calgary

Year elected:


Primary professional setting:


John L Wallace is an Adjunct Professor of Physiology & Pharmacology at the University of Calgary. He is a pharmacologist with expertise in inflammation research and in the commercialization of new technologies. His research is focused on mediators of inflammation and their contribution to mucosal injury and dysfunction. He is also interested in the mechanisms of injury induced by anti-inflammatory drugs, and the factors that regulate healing of ulcers. Dr Wallace is developing GI-sparing anti-inflammatory drugs. In 2004, Dr Wallace founded Antibe Therapeutics Inc., which became a public company, trading on the Toronto Venture Exchange, in 2013. Antibe’s lead drug, ATB-346, is in phase 2 clinical trials for treatment of osteoarthritis. He has published approximately 450 peer-reviewed papers 100 book chapters, and is among the top 0.5 per cent of biomedical scientists in terms of citations (Hirsch factor of 105; >37,000 citations).